CD274 and cancer: In a separate phase I trial of patients with various advanced cancers, an anti-PDL1 antibody (MDX-1105) also induced durable tumor regression (objective response rate, 6–17%) and prolonged stabilization of disease (12–41% at 24 week) (57).